Nicholas Procaccini, MD
Gastroenterology · Seattle, WANPI 1336351147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 29.8% of the total. 2025 is the largest year on record at $1,968, more than ten times the $98 reported in 2019.
Across 157 payments — averaging $26.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$608
- Johnson & Johnson$454
- Pfizer$268
- Madrigal Pharmaceuticals$211
- Regeneron Healthcare Solutions, Inc.$207
- plus $1K from 17 others
Across 26 payments — averaging $5621.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$62K
- Eli Lilly$51K
- Mallinckrodt Enterprises LLC$16K
- Janssen Research & Development, LLC$16K
- Gilead$2K
What the payments were for
- Food & beverage$4,07599%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $1,229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $608 |
| Johnson & Johnson | 18 | $454 |
| Pfizer | 9 | $268 |
| Madrigal Pharmaceuticals | 8 | $211 |
| Regeneron Healthcare Solutions, Inc. | 7 | $207 |
| Ipsen Biopharmaceuticals, Inc | 6 | $175 |
| Phathom Pharmaceuticals, Inc. | 9 | $158 |
| Aimmune Therapeutics, Inc. | 6 | $146 |
| Merck | 3 | $93 |
| Gilead | 2 | $91 |
| Celltrion USA Inc. | 3 | $75 |
| Lilly USA, LLC | 3 | $71 |
| Sanofi | 2 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| QOL Medical, LLC | 2 | $46 |
| Bristol Myers Squibb | 2 | $36 |
| Organon | 1 | $32 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Orphalan Inc | 1 | $29 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
| Digestive Care, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$136
How this compares
$4,124 in reported general payments places this provider in the 80th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 24 | $484 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 17 | $303 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 14 | $246 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 15 | $206 |
| Pantoprazole Sodium | 26 | $128 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Seattle
- Kris KowdleySeattle$1.4M
- Scott LeeSeattle$220K
- Alyssa ChoiSeattle$102K
- Andrew RossSeattle$99K
- Shayan IraniSeattle$57K
- Laurens JanssensSeattle$56K
- George McDonaldSeattle$53K
- Adam TempletonSeattle$49K
- Sravanthi ParasaSeattle$47K
- Liam HilsonSeattle$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.